CME Group (CME) Projected to Post Earnings on Wednesday

Key Points

• CME Group is expected to report Q3 2026 results before the market opens on October 21. Analysts forecast earnings of $2.98 per share on revenue of $1.71 billion; the company’s previous quarter exceeded consensus estimates on both earnings and revenue.
• CME shares opened at $278.03, with the stock valued at approximately $100 billion and trading at a price-to-earnings ratio of 23.5. The company pays a quarterly dividend of $1.30 per share, equivalent to a 1.9% yield.
• Wall Street’s consensus rating is “Hold,” with nine analysts rating the stock a Buy, six a Hold and three a Sell. The average analyst price target is $292.06, while recent targets range from $250 to $337.

CME Group (NASDAQ:CME - Get Free Report) is expected to be releasing its Q3 2026 results before the market opens on Wednesday, October 21st. Analysts expect CME Group to announce earnings of $2.98 per share and revenue of $1.71 billion for the quarter. Interested persons can check the company's upcoming Q3 2026 earnings report for the latest details on the call scheduled for Wednesday, October 21, 2026 at 8:30 AM ET.

CME Group (NASDAQ:CME - Get Free Report) last released its quarterly earnings data on Wednesday, July 22nd. The financial services provider reported $2.99 EPS for the quarter, topping the consensus estimate of $2.91 by $0.08. CME Group had a net margin of 63.30% and a return on equity of 15.60%. The company had revenue of $1.71 billion during the quarter, compared to the consensus estimate of $1.68 billion. During the same period last year, the firm earned $2.96 EPS. CME Group's revenue for the quarter was up .8% on a year-over-year basis. On average, analysts expect CME Group to post $12.29 EPS for the current fiscal year and $12.87 EPS for the next fiscal year.

CME Group Stock Up 0.3%

CME Group stock opened at $278.03 on Wednesday. CME Group has a 1-year low of $218.31 and a 1-year high of $329.16. The firm has a market capitalization of $99.97 billion, a price-to-earnings ratio of 23.50, a P/E/G ratio of 3.63 and a beta of 0.24. The company has a current ratio of 1.02, a quick ratio of 1.02 and a debt-to-equity ratio of 0.13. The firm has a 50 day simple moving average of $272.60 and a 200 day simple moving average of $270.72.

CME Group Announces Dividend

The business also recently announced a quarterly dividend, which was paid on Friday, September 25th. Shareholders of record on Wednesday, September 9th were given a dividend of $1.30 per share. The ex-dividend date was Wednesday, September 9th. This represents a $5.20 annualized dividend and a dividend yield of 1.9%. CME Group's dividend payout ratio is currently 44.11%.

Insider Buying and Selling

In other news, Director William R. Shepard bought 293 shares of CME Group stock in a transaction that occurred on Friday, September 25th. The shares were acquired at an average price of $268.76 per share, with a total value of $78,746.68. Following the completion of the purchase, the director directly owned 263,289 shares in the company, valued at $70,761,551.64. The trade was a 0.11% increase in their ownership of the stock. The purchase was disclosed in a filing with the SEC, which is available through this hyperlink. Also, CEO Terrence A. Duffy sold 15,000 shares of the firm's stock in a transaction dated Thursday, September 10th. The shares were sold at an average price of $274.44, for a total value of $4,116,600.00. Following the sale, the chief executive officer owned 40,630 shares in the company, valued at $11,150,497.20. The trade was a 26.96% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. 0.30% of the stock is owned by company insiders.

Wall Street Analyst Weigh In

Several brokerages have commented on CME. UBS Group raised their target price on CME Group from $260.00 to $270.00 and gave the stock a "neutral" rating in a research note on Monday, October 5th. JPMorgan Chase & Co. lifted their price objective on CME Group from $249.00 to $250.00 and gave the company an "underweight" rating in a research note on Thursday, July 23rd. Keefe, Bruyette & Woods upgraded CME Group from a "market perform" rating to an "outperform" rating and set a $305.00 target price for the company in a research report on Thursday, June 18th. Morgan Stanley boosted their target price on CME Group from $330.00 to $337.00 and gave the stock an "overweight" rating in a research report on Friday. Finally, Barclays upped their target price on CME Group from $270.00 to $281.00 and gave the stock an "equal weight" rating in a research note on Wednesday, October 7th. Nine research analysts have rated the stock with a Buy rating, six have assigned a Hold rating and three have issued a Sell rating to the company. Based on data from MarketBeat, CME Group currently has an average rating of "Hold" and a consensus target price of $292.06.

About CME Group

CME Group Inc operates global derivatives marketplaces that enable customers to manage risk and trade futures and options contracts. Its exchanges offer products linked to interest rates, equity indexes, foreign currencies, agricultural commodities, energy, metals and other asset classes.

The company also provides central counterparty clearing, settlement and related risk-management services for transactions conducted on its markets. In addition, CME Group offers market data, benchmark products and technology services that support trading, analysis and connectivity for financial institutions, businesses, professional traders and other market participants.

CME Group's history includes the Chicago Board of Trade, founded in 1848, and the Chicago Mercantile Exchange, established in 1898.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.